126 related articles for article (PubMed ID: 12103473)
1. EEG correlates of acute and chronic paroxetine treatment in depression.
Knott V; Mahoney C; Kennedy S; Evans K
J Affect Disord; 2002 May; 69(1-3):241-9. PubMed ID: 12103473
[TBL] [Abstract][Full Text] [Related]
2. Pre-treatment EEG and it's relationship to depression severity and paroxetine treatment outcome.
Knott V; Mahoney C; Kennedy S; Evans K
Pharmacopsychiatry; 2000 Nov; 33(6):201-5. PubMed ID: 11147926
[TBL] [Abstract][Full Text] [Related]
3. Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence.
Le Noury J; Nardo JM; Healy D; Jureidini J; Raven M; Tufanaru C; Abi-Jaoude E
BMJ; 2015 Sep; 351():h4320. PubMed ID: 26376805
[TBL] [Abstract][Full Text] [Related]
4. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
5. EEG gamma synchronization is associated with response to paroxetine treatment.
Arikan MK; Metin B; Tarhan N
J Affect Disord; 2018 Aug; 235():114-116. PubMed ID: 29655071
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of Paroxetine 20 mg daily in the treatment of depression and depression associated anxiety.
Chaudhry HR; Qureshi Z; Tareen IA; Yazdani I
J Pak Med Assoc; 2002 Nov; 52(11):518-25. PubMed ID: 12585372
[TBL] [Abstract][Full Text] [Related]
7. Clinical application of paroxetine for tapering benzodiazepine use in non-major-depressive outpatients visiting an internal medicine clinic.
Nakao M; Takeuchi T; Nomura K; Teramoto T; Yano E
Psychiatry Clin Neurosci; 2006 Oct; 60(5):605-10. PubMed ID: 16958945
[TBL] [Abstract][Full Text] [Related]
8. Paroxetine in the treatment of depressed patients with haematological malignancy: an open-label study.
Pae CU; Kim YJ; Won WY; Kim HJ; Lee S; Lee CU; Lee SJ; Kim DW; Lee C; Min WS; Kim CC; Paik IH; Serretti A
Hum Psychopharmacol; 2004 Jan; 19(1):25-9. PubMed ID: 14716708
[TBL] [Abstract][Full Text] [Related]
9. Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine.
Baldwin D; Bridgman K; Buis C
J Psychopharmacol; 2006 Jan; 20(1):91-6. PubMed ID: 16204325
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Hypericum extract WS 5570 and paroxetine in ongoing treatment after recovery from an episode of moderate to severe depression: results from a randomized multicenter study.
Anghelescu IG; Kohnen R; Szegedi A; Klement S; Kieser M
Pharmacopsychiatry; 2006 Nov; 39(6):213-9. PubMed ID: 17124643
[TBL] [Abstract][Full Text] [Related]
11. Cerebral glucose metabolic response to combined total sleep deprivation and antidepressant treatment in geriatric depression.
Smith GS; Reynolds CF; Pollock B; Derbyshire S; Nofzinger E; Dew MA; Houck PR; Milko D; Meltzer CC; Kupfer DJ
Am J Psychiatry; 1999 May; 156(5):683-9. PubMed ID: 10327899
[TBL] [Abstract][Full Text] [Related]
12. The comparative effectiveness of electroencephalographic indices in predicting response to escitalopram therapy in depression: A pilot study.
Baskaran A; Farzan F; Milev R; Brenner CA; Alturi S; Pat McAndrews M; Blier P; Evans K; Foster JA; Frey BN; Giacobbe P; Lam RW; Leri F; MacQueen GM; Müller DJ; Parikh SV; Rotzinger S; Soares CN; Strother SC; Turecki G; Kennedy SH;
J Affect Disord; 2018 Feb; 227():542-549. PubMed ID: 29169123
[TBL] [Abstract][Full Text] [Related]
13. CYP1A2 genetic polymorphisms are associated with treatment response to the antidepressant paroxetine.
Lin KM; Tsou HH; Tsai IJ; Hsiao MC; Hsiao CF; Liu CY; Shen WW; Tang HS; Fang CK; Wu CS; Lu SC; Kuo HW; Liu SC; Chan HW; Hsu YT; Tian JN; Liu YL
Pharmacogenomics; 2010 Nov; 11(11):1535-43. PubMed ID: 21121774
[TBL] [Abstract][Full Text] [Related]
14. EEG power, frequency, asymmetry and coherence in male depression.
Knott V; Mahoney C; Kennedy S; Evans K
Psychiatry Res; 2001 Apr; 106(2):123-40. PubMed ID: 11306251
[TBL] [Abstract][Full Text] [Related]
15. Differences in immunomodulatory properties between venlafaxine and paroxetine in patients with major depressive disorder.
Chen CY; Yeh YW; Kuo SC; Liang CS; Ho PS; Huang CC; Yen CH; Shyu JF; Lu RB; Huang SY
Psychoneuroendocrinology; 2018 Jan; 87():108-118. PubMed ID: 29055264
[TBL] [Abstract][Full Text] [Related]
16. Paroxetine in the treatment of primary insomnia: preliminary clinical and electroencephalogram sleep data.
Nowell PD; Reynolds CF; Buysse DJ; Dew MA; Kupfer DJ
J Clin Psychiatry; 1999 Feb; 60(2):89-95. PubMed ID: 10084634
[TBL] [Abstract][Full Text] [Related]
17. A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression.
Barbee JG; Thompson TR; Jamhour NJ; Stewart JW; Conrad EJ; Reimherr FW; Thompson PM; Shelton RC
J Clin Psychiatry; 2011 Oct; 72(10):1405-12. PubMed ID: 21367355
[TBL] [Abstract][Full Text] [Related]
18. Comparison of escitalopram and paroxetine in the treatment of major depressive disorder.
Lin HL; Hsu YT; Liu CY; Chen CH; Hsiao MC; Liu YL; Shen WW; Hsiao CF; Liu SI; Chang LH; Tang HS; Lai HL; Lin PS; Lin KM; Tsou HH
Int Clin Psychopharmacol; 2013 Nov; 28(6):339-45. PubMed ID: 23881184
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of paroxetine for the treatment of depression in the context of HIV infection.
Grassi B; Gambini O; Garghentini G; Lazzarin A; Scarone S
Pharmacopsychiatry; 1997 Mar; 30(2):70-1. PubMed ID: 9131727
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis.
Ehde DM; Kraft GH; Chwastiak L; Sullivan MD; Gibbons LE; Bombardier CH; Wadhwani R
Gen Hosp Psychiatry; 2008; 30(1):40-8. PubMed ID: 18164939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
